NAVIGATING the NEW ERA in IPF: Idiopathic Pulmonary Fibrosis
|
|
- Cordelia Parker
- 5 years ago
- Views:
Transcription
1 NAVIGATING the NEW ERA in IPF: Idiopathic Pulmonary Fibrosis Mark J Rumbak, MD Division Director Pulmonary, Critical Care and Sleep Medicine Morsani College of Medicine University of South Florida, Tampa ILD of Known Cause or Association Medications Radiation Connective Tissue Disease Vasculitis & DAH Hypersensitivity Pneumonitis Pneumoconioses Interstitial Lung Diseases Idiopathic Interstitial Pneumonias Adapted from: ATS/ERS Guidelines for IIP. AJRCCM. 2002;165: Sarcoidosis & Other Granulomatous Diseases Other LAM Pulmonary LCH Eosinophilic Pneumonias Alveolar Proteinosis Genetic Syndromes Diffuse Parenchymal Lung Disease (DPLD) DPLD of known cause, eg, drugs or association, eg, collagen vascular disease Idiopathic interstitial pneumonias Granulomatous DPLD, eg, sarcoidosis Other forms of DPLD, eg, LAM, HX, etc Idiopathic pulmonary fibrosis IIP other than idiopathic pulmonary fibrosis Desquamative interstitial pneumonia Acute interstitial pneumonia Nonspecific interstitial pneumonia (provisional) Respiratory bronchiolitis interstitial lung disease Cryptogenic organizing pneumonia Lymphocytic interstitial pneumonia Pleuroparenchymal fibroelastosis Travis WD, et al; ATS/ERS Committee on Idiopathic Interstitial Pneumonias. Am J Respir Crit Care Med. 2013;188(6):
2 Cumulative Proportion Surviving Diagnosis Matters! IPF/UIP Confers a Poor Prognosis Time (years) Flaherty KR, et al. Eur Respir J. 2002;19: Parameter HR (95% CI) IPF Dx (5.5, 147) Age 0.99 (0.95, 1.03) Female sex 0.31 (0.13, 0.72) Smoker 0.30 (0.13, 0.72) Physio CRP 1.06 (1.01, 1.11) Onset Sx (yrs) 1.02 (0.93, 1.12) CTfib score (0.29, 2.04) Correct diagnosis appropriate management 2011 ATS/ERS Diagnostic Criteria for IPF Exclusion of known causes of ILD* AND *also known as diffuse parenchymal lung disease, DPLD Raghu G, et al. Am J Respir Crit Care Med. 2011;183: UIP pattern on HRCT without surgical biopsy OR Definite/possible UIP pattern on HRCT with a surgical lung biopsy showing definite/probable UIP Pulmonary Function Tests Spirometry Reduced FVC and TLC Normal or increased FEV 1 /FVC ratio Restriction often accompanied by some obstruction Impaired gas exchange Decreased DL CO, PaO 2 Desaturation on exercise oximetry Increased A apo 2 gradient Normal PFTs do not exclude ILD Emphysema + Interstitial Lung Disease Known Causes of ILD: History & Physical Exam Drugs eg, Amiodarone, bleomycin, nitrofurantoin Radiation External beam radiation therapy to thorax Connective Tissue Diseases Rheumatoid arthritis Systemic sclerosis (scleroderma) Idiopathic inflammatory myopathies Vasculitis Occupational/Environmental Inorganic antigens (Pneumoconioses) Asbestosis Coal worker s pneumoconiosis Silicosis Organic antigens (Hypersensitivity Pneumonitis) Birds Mold 2
3 Advanced Sclerodactyly Gottron's Papules in Dermatomyositis Accessed July Accessed July Mechanic's Hands in Anti Synthetase Syndrome Raynaud's Phenomenon Accessed July Accessed July
4 Puffy Fingers in Early Scleroderma or Mixed CTD Digital Clubbing Accessed July Reynen K, et al. N Engl J Med. 2000; 343:1235 NEJM, 2001 Telemere Syndrome Serological Evaluation Minimum: ANA, RF, CCP (ATS/ERS guidelines) Based on history & physical exam, consider: Extractable nuclear antigen (ENA) autoantibody panel Anti centromere antibody ESR & CRP MPO/PR3 (ANCA) antibodies Anti cardiolipin antibodies, lupus anticoagulant Creatine kinase, aldolase Hypersensitivity pneumonitis panel Should be performed before a biopsy 4
5 UIP Pattern Idiopathic Pulmonary Fibrosis Normal Lung Usual Interstitial Pneumonia Hodnett PA, et al. Am J Respir Crit Care Med. 2013;188:
6 Higher Mortality Associated With Delays in Accessing Care Survival Years Lamas DJ, et al. Am J Respir Crit Care Med. 2011;184:
7 HRCT Criteria for UIP Diffusing Capacity Predicts Survival in IPF UIP Pattern Possible UIP Pattern Subpleural, basal predominance + + Reticular abnormality + + Honeycombing (+/ traction bronchiectasis) + Absence of inconsistent features + + Percent Survival DL co 50% DL co 35 49% Dl co < 35% P= Months Raghu G, et al. Am J Respir Crit Care Med. 2011;183: Nathan SD, et al. Chest. 2011;140: FVC Predicts Survival in IPF Percent Survival Nathan SD, et al. Chest. 2011;140: Months FVC 70% FVC 55 69% FVC < 55% P= Survival Probability 6MWT Parameters Predict Survival in IPF Which 6MWT parameter best predicts survival in IPF? Baseline 6MWT distance Time Weeks du Bois RM, et al. Eur Respir J. 2014;43(5): Swigris JJ, et al. Chest. 2009;136: P = 0.01 Survival Probability HR 1 minute after 6MWT Days of Follow Up 6MWT distance at 24 weeks Time Weeks P = > 13bpm 13bpm P <
8 Linking IPF Pathogenesis to Potential Therapies Three Recent IPF Clinical Trials American Thoracic Society 2014 PANTHER ASCEND INPULSIS N acetylcysteine (NAC) pirfenidone nintedanib (BIBF1120) Ahluwalia N, et al. Am J Respir Crit Care Med Aug 4. [Epub ahead of print]. RCTs in IPF INPULSIS 2 14 INPULSIS 1 14 ASCEND 14 Pre 2011 Early Evidence for a NAC Cocktail ATS PANTHER 12 Shulgina 12 Raghu 12 King 11 Noble 11 Richeldi 11 PANTHER 14 Acetylcysteine + azathioprine + + steroids + steroids Placebo + + azathioprine + + steroids Noble 11 Raghu 08 Taniguchi 10 Daniels 10 Kubo 05 Azuma 05 King 08 Demedts 05 Ziesche 99 Douglas 98 Raghu 99 Raghu 04 ACE IPF 12 STEP IPFnet 10 King 09 Slide courtesy of L. Richeldi Demedts M, et al. New Engl J Med. 2005;353:
9 Possible NAC Mechanisms of Action PANTHER 2012 Pre 2011 ATS Increase glutathione antioxidation Downregulate lysyl oxidase (LOX) activity, (essential for collagen deposition) Li S, et al. Respiration. 2012;84(6): Rushworth GF, et al. Pharmacol Ther. 2014;141(2): Raghu G, et al. N Engl J Med. 2012;366: Pre 2011 PANTHER 2012 Interim Results ATS 2011 Primary Triple Therapy Placebo P value FVC (liters) PANTHER 2014 ATS Pre Triple therapy has no benefit for FVC Increased risk of death Probability Time to Death Kaplan Meier Analysis Weeks Since Randomization HR 9.26 (95% CI ) P = 0.01 Raghu G, et al. N Engl J Med. 2012;366: Martinez FJ, et al. N Engl J Med. 2014;370(22):
10 NAC Does Not Reduce FVC Decline Possible Mechanisms of Pirfenidone Action Conclusion: NAC offered no significant benefit with respect to the preservation of FVC in patients with IPF with mild to moderate impairment in lung function Antifibrotic Molecular target unclear Active in several animal models of fibrosis (lung, liver, kidney) TNF α IL 6 TGF β IL 6 Pirfenidone Collagen MMPs Collagenases ROIs Martinez FJ, et al. N Engl J Med. 2014;370(22): Hilberg O, et al. Clin Respir J. 2012;6: CAPACITY 2011 CAPACITY 2 Pre 2011 ATS 2011 CAPACITY Acute Exacerbations Punctuate Slow Decline (5 10% of patients per year) One pirfenidone trial was positive, one was negative CAPACITY 1 placebo group FVC declined more slowly than expected Noble P, et al. Lancet. 2011;377: King TE Jr, et al. Lancet. 2011;378(9807):
11 ASCEND 2014 ATS Pre Primary ASCEND Endpoint Achieved Primary Endpoint Patients with 10% FVC Decline or Death (%) 48% Relative Reduction Week King TE, et al. N Engl J Med. 2014;370(22): Pirfenidone Increased Progression Free Survival* Pirfenidone Reduces Loss of FVC Mean Change (ml) Rank ANCOVA P value < at each indicated time point 235 ml 428 ml *Progression is first occurrence of death, 10% FVC, or 50 m 6MWD King TE, et al. N Engl J Med. 2014;370(22): King TE, et al. N Engl J Med. 2014;370(22): Week <
12 ASCEND Adverse Events Possible Mechanisms of Nintedanib Action Adverse Event Pirfenidone (%) Placebo (%) (N = 278) (N = 277) Δ (%) Nausea Rash Dyspepsia Anorexia GERD Weight Loss Insomnia Dizziness Vomiting Dyspnea Cough IPF King TE, et al. N Engl J Med. 2014;370(22): Triple kinase inhibitor Phosphatase activator Antiangiogenic, antitumor activity VEGF Hilberg F, et al. Cancer Res. 2008;68(12): Tai WT, et al. J Hepatol. 2014;61(1): Nintedanib PDGF FGF SHP 1 Pleiotropic Effects Nintedanib Showed Promise for FVC Endpoint Pre 2011 ATS INPULSIS 2014 ATS Pre Richeldi L, et al. N Engl J Med.2011:365;
13 Primary INPULSIS Endpoint Achieved Annual Rate of Change of FVC INPULSIS 1 52% Relative Reduction INPULSIS 2 45% Relative Reduction Nintedanib Reduces Loss of FVC Mean Observed Change from Baseline in FVC (ml) INPULSIS 1 INPULSIS 2 Richeldi L, et al. N Engl J Med. 2014;370(22): Nintedanib Placebo Richeldi L, et al. N Engl J Med. 2014;370(22): Week Mixed Findings for Time to First Acute Exacerbation Cumulative Incidence of First Acute Exacerbation (%) INPULSIS 1 INPULSIS 2 Common Nintedanib Adverse Events Event Nintedanib (n = 309) INPULSIS 1 Placebo (n = 204) Nintedanib (n = 329) INPULSIS 2 Placebo (n = 219) Any (%) Diarrhea (%) Nausea(%) Richeldi L, et al. N Engl J Med. 2014;370(22): Days Richeldi L, et al. N Engl J Med. 2014;370(22):
14 2015 vs 2011 ATS/ERS Treatment Recommendations: For Use Raghu G, et al; ATS, ERS, JRS, and ALAT. Am J Respir Crit Care Med. 2015;192(2):e3 e19. Raghu G, et al; ATS, ERS, JRS, and ALAT. Am J Respir Crit Care Med. 2015;192(2):e3 e19. Current Phase 2 Trials for IPF Next Generation Therapy? Trial Target N Primary Endpoint Co trimoxazole (Ph 3) Pneumocystis jiroveci 56 Change in FVC or respir. Hospital n FG 3019 Anti CTGF 90 Change in FVC from baseline Rituximab CD Titers of anti HEp 2 autoantibodies Simtuzumab Anti LOXL2 500 PFS GC 1008 TGF 25 Safety, tolerability, PK QAX576 Anti IL Safety, tolerability, FVC Tralokinumab Anti IL Change in FVC from baseline STX 100 αvβ6 32 Adverse events BMS LPA Receptor 300 Rate of change in FVC Ongoing Phase 2 Drug Trials SAR (N = 300) FG 3019 (N = 136) BMS (N = 135) BG00011 (N = 40) Tralokinumab (N = 186) Simtuzumab (N = 500) Lebrikizumab (N = 300) TD139 (N = 60) Slide courtesy of L. Richeldi 14
15 Lung Transplantation for IPF: 2014 Referral Guidelines Histopathologic or radiographic evidence of usual interstitial pneumonitis (UIP) Abnormal lung function: FVC < 80% predicted or DL CO < 40% predicted Any dyspnea or functional limitation attributable to lung disease Any oxygen requirement, even if only during exertion Delayed Care Associated with Higher Mortality P for trend = 0.04 Weill D, et al. J Heart Lung Transplant.2014 Jun 26. [Epub ahead of print]. Lamas et al. Am J Respir Crit Care Med. 2011;184: Lung Transplantation is Increasing COPD IPF CF Common Complications and Comorbidities of IPF GERD Pulmonary hypertension Emphysema Acute exacerbation OSA CVD Thromboembolism Depression Accessed August
16 IPF and GERD GERD Diagnosis Barium swallow Esophageal manometry 24 hour ph probe Treatment PPI s Nissen fundoplication WRAP IPF trial ClinicalTrials.gov: NCT Lee JS, et al. Am J Med. 2010;123(4): Raghu G, et al. Eur Respir J. 2006;27: GERD Treatment and Survival Distribution of mpaps in IPF Patients Survival Not taking GERD medications Taking GERD medications Frequency Time to Event (days) Lee JS, et al. Am J Respir Crit Care Med. 2011;184(12): mpap Lettieri et al. Chest : PAH: mpap > 25 mm Hg 16
17 Mean Pulmonary Artery Pressure: Prognostic Value in IPF Cumulative Probability to Survival P < n = 54 n = 25 No (mpap 25 mm Hg) Yes (mpap > 25 mm Hg) Years to Event Lettieri CJ, et al. Chest. 2006;129: ATS/ERS Recommendation PH should not be treated in the majority of patients with IPF, but treatment may be a reasonable choice in a minority (weak recommendation, very low quality evidence). ( )* In patients with moderate to severe PH (mpap > 35 mm Hg) documented by right heart catheterization, a trial of vasomodulatory therapy may be indicated It is not clear if IPF with PH represents a distinct clinical phenotype (IPF PH) Raghu G, et al. Am J Respir Crit Care Med. 2011;183(6): * ( ) = GRADE quality of evidence very low Combined Pulmonary Fibrosis and Emphysema Syndrome (CPFE) Management of Patients With Combined Pulmonary Fibrosis and Emphysema (CPFE) No specific treatment for CPFE Absence of specific trials or prospective data IPF trials not adequate Smoking cessation; bronchodilators; supportive care; oxygen supplementation; lung transplant Discuss corticosteroids +/ azathioprine if NSIP considered Adapted from ERS/ESC guidelines, Galiè N et al. Eur Respir J. 2009;34:
18 Management of Patients With Acute Exacerbations Exclude other causes Infection CHF Pulmonary embolism Ischemic heart disease HRCT Bronchoscopy (if permitted by medical status) Patients usually treated with broad spectrum antibiotics and corticosteroids (unproven efficacy) Walter N, et al. Proc Am Thorac Soc. 2006;3: ATS/ERS Recommendation The majority of patients with acute exacerbation of IPF should be treated with corticosteroids, but corticosteroids may not be reasonable in a minority (weak recommendation, very low quality evidence). Raghu G, et al. Am J Respir Crit Care Med. 2011;183(6): Sleep Disruption is Common in IPF Impaired physical and social functioning 1 Sleep quality should be a primary therapeutic goal Nocturnal hypoxemia is common Associated with significant sleep disruption, 1 decreased energy levels impaired physical functioning 2 Daytime SpO 2 is a strong predictor of nocturnal SpO 2 3,4 Daytime spirometric measures are poor predictors of nocturnal hypoxia Clinical trial of supplemental oxygen is recruiting (clinicaltrials.gov NCT ) 1. Mermigkis C, et al. Med Princ Pract. 2009;18: Clark M, et al. Thorax. 2001;56: Douglas NJ, et al. Am Rev Respir Dis. 1990;141: Cormick W, et al. Thorax. 1986;41: Cardiovascular Disease in IPF Prevalence: 20% of IPF patients have comorbid CVD CVD diagnosed during follow up significantly increased mortality (HR 4.7) Increased incidence of ACS Angina DVT CAD CHF and CAD account for 1/3 deaths in IPF Hyldgaard C, et al. Respir Med. 2014;108(4): Hubbard RB, et al. Am J Respir Crit Care Med 2008; 178: Izbicki G, et al. Respir Med. 2009; 103(9):
19 Odds Ratios for Risk Factors of CVD for Incident Cases of IPF UK database: The Health Improvement Network (THIN) Risk factor Cases (n=3211) (%) Controls (n=12,307) (%) Odds Ratio (95% CI) P value* Hypertension ( ) <0.001 Diabetes ( ) Ex smoker ( ) Current smoker ( ) <0.001 Rate Ratios for Ischemic Heart Disease and Stroke IPF vs Control Subjects Outcome # events in cases Crude rate in cases (per 1000 pyrs) # events in controls Crude rate in controls (per 1000 pyrs) Rate Ratio P value* IHD < Stroke * Likelihood ratio test BMI > ( ) <0.001 * Likelihood ratio test Accessed August Accessed August Cumulative Incidence of IHD is Higher With IPF Percent survival N=21 N=52 P=0.003 Significant CAD Mild or no CAD Days Accessed August Nathan SN, et al. Respir Med. 2010:104:
20 VTE is Elevated in Patients With IPF National Center for Health Statistics, ,450,489 total records 218,991 patients with IPF 3815 (1.74%) also diagnosed with VTE Increased risk of IPF VTE decreased life span of patients with IPF Data suggest a link between a pro fibrotic and a procoagulant state Sprunger DB, et al. Eur Respir J. 2012;39(1): Depression in IPF Observed in ~25% of patients with IPF 9.8% in a general population of elderly subjects 26% in patients with COPD Correlated strongly and independently with dyspnea pain sleep quality FVC Baseline depression score was the strongest predictor of depression score at 6 months (r = 0.59, P < ) Ryerson CJ, et al. Respirology ;17(3): Conclusions Comorbidities associated with IPF such as GERD, CPFE, CVD, sleep apnea, and depression should be treated Clinical trials testing drugs approved for pulmonary hypertension in patients with IPF and PH have been negative on IPF endpoints Other endpoints have been positive Guidelines recommend against treating IPF patients for PH Acute exacerbation is a serious complication of IPF 20
Update on Therapies for Idiopathic Pulmonary Fibrosis. Outline
Update on Therapies for Idiopathic Pulmonary Fibrosis Paul Wolters Associate Professor University of California, San Francisco Outline Classification of Interstitial lung disease Clinical classification
More informationNew Therapies and Trials in IPF
Conflict of interest disclosure I have the following real or perceived conflicts of interest that relate to this presentation: New Therapies and Trials in IPF Talmadge E. King, Jr., M.D. Julius R. Krevans
More informationINTERSTITIAL LUNG DISEASES: FOCUS ON IDIOPATHIC PULMONARY FIBROSIS (IPF)
INTERSTITIAL LUNG DISEASES: FOCUS ON IDIOPATHIC PULMONARY FIBROSIS (IPF) Marilyn K. Glassberg Csete, M.D. Professor of Medicine, Surgery, and Pediatrics Director, Interstitial and Rare Lung Disease Program
More informationNew Horizons The Future of IPF and ILD
New Horizons The Future of IPF and ILD Talmadge E. King, Jr., M.D. Julius R. Krevans Distinguished Professorship in Internal Medicine Chair, Department of Medicine University of California San Francisco
More informationOverview of Idiopathic Pulmonary Fibrosis: Diagnosis and Therapy
Overview of Idiopathic Pulmonary Fibrosis: Diagnosis and Therapy Jeff Swigris, DO, MS Director, ILD Program National Jewish Health Disclosures Speaker - Boehringer Ingelheim and Genentech Objectives Describe
More informationTherapies for Idiopathic Pulmonary Fibrosis Pharmacologic, Non-Pharmacologic
Therapies for Idiopathic Pulmonary Fibrosis Pharmacologic, Non-Pharmacologic Amy Olson, MD, MSPH Associate Professor, Division of Pulmonary and Critical Care Medicine National Jewish Health, Denver, CO
More informationConnective Tissue Disorder- Associated Interstitial Lung Disease (CTD-ILD) and Updates
Connective Tissue Disorder- Associated Interstitial Lung Disease (CTD-ILD) and Updates Maria Elena Vega, M.D Assistant Professor of Medicine Lewis Katz School of Medicine at Temple University Nothing to
More informationPatient with FVC>90% predicted. Demosthenes Bouros, Vasilios Tzilas University of Athens
Patient with FVC>90% predicted Demosthenes Bouros, Vasilios Tzilas University of Athens CASE OVERVIEW A 63-year-old, male patient with progressive exertional dyspnoea lasting for 2 years and dry cough
More informationIdiopathic Pulmonary Fibrosis Treatable and Not Idiopathic
Idiopathic Pulmonary Fibrosis Treatable and Not Idiopathic Brett Ley, MD University of California San Francisco CTS 1/26/18 Disclosures Speaker s bureau honorarium from Genentech (makers of pirfenidone)
More informationDisclosures. Traditional Paradigm. Overview 4/17/2010. I have relationships with the following organizations and companies:
Disclosures Pharmacological Therapy for ILD What to Use and How to Use It Harold R Collard MD Interstitial Lung Disease Program University of California San Francisco (UCSF) I have relationships with the
More informationInterstitial Lung Disease (ILD)
Interstitial Lung Disease (ILD) ILD comprises more than 130 distinct disorders Characterized by cellular proliferation, cellular infiltration, and/or fibrosis of the lung parenchyma not due to infection
More information4/17/2010 C ini n ca c l a Ev E a v l a ua u t a ion o n of o ILD U dat a e t e i n I LDs
Update in ILDs Diagnosis 101: Clinical Evaluation April 17, 2010 Jay H. Ryu, MD Mayo Clinic, Rochester MN Clinical Evaluation of ILD Outline General aspects of ILDs Classification of ILDs Clinical evaluation
More informationIPF AND OTHER FIBROSING LUNG DISEASE: WHAT DRUGS MIGHT WORK AND ON WHOM DO THEY W ORK?
IPF AND OTHER FIBROSING LUNG DISEASE: WHAT DRUGS MIGHT WORK AND ON WHOM DO THEY W ORK? KEVIN K. BROWN, MD PROFESSOR AND VICE CHAIRMAN, DEPARTMENT OF MEDICINE NATIONAL JEWISH HEALTH DENVER, CO Kevin K.
More informationLines and crackles. Making sense of ILD
Lines and crackles Making sense of ILD Case JM 65 year old male Gradual shortness of breath, going on over a year Some dry cough Ex-smoker, quit 10 years ago Crackles in the bases CXR presented Sent to
More informationDIAGNOSTIC NOTE TEMPLATE
DIAGNOSTIC NOTE TEMPLATE SOAP NOTE TEMPLATE WHEN CONSIDERING A DIAGNOSIS OF IDIOPATHIC PULMONARY FIBROSIS (IPF) CHIEF COMPLAINT HISTORY OF PRESENT ILLNESS Consider IPF as possible diagnosis if any of the
More informationDiffuse Interstitial Lung Diseases: Is There Really Anything New?
: Is There Really Anything New? Sujal R. Desai, MBBS, MD ESTI SPEAKER SUNDAY Society of Thoracic Radiology San Antonio, Texas March 2014 Diffuse Interstitial Lung Disease The State of Play DILDs Is There
More informationWim Wuyts. Treatment of idiopathic interstitial pneumonias. March 12 th Interstitial lung diseases state of the art.
nterstitial ungdiseases euven Department of pneumology Unit for interstitial lung diseases University Hospitals Leuven March 12 th 2015 Interstitial lung diseases state of the art Treatment of idiopathic
More informationChallenges in Pulmonary and Critical Care: 2018
Challenges in Pulmonary and Critical Care: 2018 Interstitial Lung Disease: Evolving Our Understanding of a Deadly Disease 1 Faculty Kevin Flaherty, MD, MS Professor in Pulmonary and Critical Care Medicine
More informationCTD-related Lung Disease
13 th Cambridge Chest Meeting King s College, Cambridge April 2015 Imaging of CTD-related Lung Disease Dr Sujal R Desai King s College Hospital, London Disclosure Statement No Disclosures / Conflicts of
More informationDiagnosing Idiopathic Pulmonary Fibrosis on Evidence-Based Guidelines
Diagnosing Idiopathic Pulmonary Fibrosis on Evidence-Based Guidelines Rebecca Keith, MD Assistant Professor, Division of Pulmonary and Critical Care Medicine National Jewish Health, Denver, CO Objectives
More informationDiagnostic challenges in IPF
Medicine, Nursing and Health Sciences Diagnostic challenges in IPF Dr Ian Glaspole Central and Eastern Clinical School, Alfred Hospital and Monash University March 2015 Disclosures Consultancy fees from
More informationNintedanib and Pirfenidone: New Medications in the Management of Idiopathic Pulmonary Fibrosis
Nintedanib and Pirfenidone: New Medications in the Management of Idiopathic Pulmonary Fibrosis Brad Zimmermann, PharmD, MBA Pharmacy Grand Rounds May 02, 2017 Rochester, Minnesota 2017 MFMER slide-1 Objectives
More informationProgress in Idiopathic Pulmonary Fibrosis
Progress in Idiopathic Pulmonary Fibrosis David A. Lynch, MB Disclosures Progress in Idiopathic Pulmonary Fibrosis David A Lynch, MB Consultant: t Research support: Perceptive Imaging Boehringer Ingelheim
More informationPresente e futuro della terapia della fibrosi polmonare idiopatica
Presente e futuro della terapia della fibrosi polmonare idiopatica Antonella Caminati U.O. di Pneumologia e Terapia Semi Intensiva Servizio di Fisiopatologia Respiratoria ed Emodinamica Polmonare Osp.
More informationStrategies for Updated Treatment Options for IPF
Strategies for Updated Treatment Options for IPF Paul W. Noble, MD Vera and Paul Guerin Family Distinguished Chair in Pulmonary Medicine Professor and Chair Department of Medicine Director, Women's Guild
More informationDisclosures. Fibrotic lung diseases: Basic Principles, Common Problems, and Reporting. Relevant financial relationships: None. Off-label usage: None
Fibrotic lung diseases: Basic Principles, Common Problems, and Reporting Brandon T. Larsen, MD, PhD Senior Associate Consultant Department of Laboratory Medicine and Pathology Mayo Clinic Arizona Arizona
More informationCase Presentations in ILD. Harold R. Collard, MD Department of Medicine University of California San Francisco
Case Presentations in ILD Harold R. Collard, MD Department of Medicine University of California San Francisco Outline Overview of diagnosis in ILD Definition/Classification High-resolution CT scan Multidisciplinary
More informationA case of a patient with IPF treated with nintedanib. Prof. Kreuter and Prof. Heussel
A case of a patient with IPF treated with nintedanib Prof. Kreuter and Prof. Heussel Case Overview This case describes the history of a patient with IPF who, at the time of diagnosis, had symptoms typical
More informationFinancial disclosure COMMON DIAGNOSES IN HRCT. High Res Chest HRCT. HRCT Pre test. I have no financial relationships to disclose. Anatomy Nomenclature
Financial disclosure I have no financial relationships to disclose. Douglas Johnson D.O. Cardiothoracic Imaging Gaston Radiology COMMON DIAGNOSES IN HRCT High Res Chest Anatomy Nomenclature HRCT Sampling
More informationINTERSTITIAL LUNG DISEASE. Radhika Reddy MD Pulmonary/Critical Care Long Beach VA Medical Center January 5, 2018
INTERSTITIAL LUNG DISEASE Radhika Reddy MD Pulmonary/Critical Care Long Beach VA Medical Center January 5, 2018 Interstitial Lung Disease Interstitial Lung Disease Prevalence by Diagnosis: Idiopathic Interstitial
More informationPerspectives ILD Diagnosis and Treatment in 5-10 years
Perspectives ILD Diagnosis and Treatment in 5-10 years Brett Ley, MD Department of Medicine The (Near) Future of ILD Diagnosis and Treatment 1. Combination therapy for Idiopathic Pulmonary Fibrosis 2.
More informationOFEV MEDIA BACKGROUNDER
OFEV MEDIA BACKGROUNDER 1 What is OFEV (nintedanib*)? 2 How does OFEV (nintedanib*) work? 3 Data overview 4 OFEV (nintedanib*) approval status 1 What is OFEV (nintedanib*)? OFEV (nintedanib*) is a small
More informationConflicts of Interest. Advisory Board: Boehringer-Ingleheim, Genentech/Roche DSMB: Bristol-Myers Squibb, Fibrogen Clinical Endpoint Committee; Merck
Conflicts of Interest Advisory Board: Boehringer-Ingleheim, Genentech/Roche DSMB: Bristol-Myers Squibb, Fibrogen Clinical Endpoint Committee; Merck The Idiopathic Interstitial Pneumonias Idiopathic pulmonary
More informationA Review of Interstitial Lung Diseases. Paul J. Wolters, MD Associate Professor Department of Medicine University of California San Francisco
A Review of Interstitial Lung Diseases Paul J. Wolters, MD Associate Professor Department of Medicine University of California San Francisco Outline Overview of diagnosis in ILD Why it is important Definition/Classification
More information9/12/18. Emerging Challenges in Primary Care: Navigating the Maze of Interstitial Lung Disease: Improving Outcomes through Early Diagnosis
Emerging Challenges in Primary Care: 2018 Navigating the Maze of Interstitial Lung Disease: Improving Outcomes through Early Diagnosis Faculty Kevin Flaherty, MD, MS Professor in Pulmonary and Critical
More information5/9/2015. Multi-disciplinary Approach to Diffuse Lung Disease: The Imager s Perspective. No, I am not a pulmonologist! Radiology
Multi-disciplinary Approach to Diffuse Lung Disease: The Imager s Perspective No, I am not a pulmonologist! Radiology Pathology Clinical 1 Everyone needs a CT Confidence in diagnosis Definitive HRCT +
More informationCLEARING THE AIR ON DIFFUSE PARENCHYMAL (INTERSTITIAL) LUNG DISEASE (ILD)
CLEARING THE AIR ON DIFFUSE PARENCHYMAL (INTERSTITIAL) LUNG DISEASE (ILD) David Northrop MBA, RRT Assistant Director of Respiratory Therapy Services The University of Kansas Health System Clinical Assistant
More informationA Review of Interstitial Lung Diseases
Outline A Review of Interstitial Lung Diseases Paul J. Wolters, MD Associate Professor Department of Medicine University of California San Francisco Overview of diagnosis in ILD Why it is important Definition/Classification
More informationINHALED TREPROSTINIL IN PULMONARY HYPERTENSION DUE TO INTERSTITIAL LUNG DISEASE (PH-ILD)
THE INCREASE STUDY INHALED TREPROSTINIL IN PULMONARY HYPERTENSION DUE TO INTERSTITIAL LUNG DISEASE (PH-ILD) Peter Smith, PharmD Senior Director Product Development, United Therapeutics Corporation 2 SAFE
More informationPulmonary manifestations of CTDs Diagnosis, differential diagnosis and treatment
Prague, June 2014 Pulmonary manifestations of CTDs Diagnosis, differential diagnosis and treatment Katerina M. Antoniou, MD, PhD As. Professor in Thoracic Medicine ERS ILD Group Secretary Medical School,
More information11/10/2014. Multi-disciplinary Approach to Diffuse Lung Disease: The Imager s Perspective. Radiology
Multi-disciplinary Approach to Diffuse Lung Disease: The Imager s Perspective Radiology Pathology Clinical 1 Role of HRCT Diagnosis Fibrosis vs. inflammation Next step in management Response to treatment
More informationManagement of Co morbidities in Idiopathic Pulmonary Fibrosis. Disclosures
Management of Co morbidities in Idiopathic Pulmonary Fibrosis Joyce S. Lee, MD MAS Director, Interstitial Lung Disease Clinic University of California, San Francisco Disclosures Intermune, advisory board
More informationNINTEDANIB MEDIA BACKGROUNDER
NINTEDANIB MEDIA BACKGROUNDER 1. What is nintedanib? 2. How does nintedanib work? 3. Data overview 4. International treatment guidelines for IPF 1. What is nintedanib? Nintedanib (OFEV a ) is a small molecule
More informationDr. Tracy Luckhardt Division of Pulmonary, Allergy and Critical Care Medicine University of Alabama at Birmingham
Dr. Tracy Luckhardt Division of Pulmonary, Allergy and Critical Care Medicine University of Alabama at Birmingham Types of Questions you Will Be Asked Rhetorical Participatory Disclosure of Relevant Financial
More informationDifferential diagnosis
Differential diagnosis Idiopathic pulmonary fibrosis (IPF) is part of a large family of idiopathic interstitial pneumonias (IIP), one of four subgroups of interstitial lung disease (ILD). Differential
More informationOutline Definition of Terms: Lexicon. Traction Bronchiectasis
HRCT OF IDIOPATHIC INTERSTITIAL PNEUMONIAS Disclosures Genentech, Inc. Speakers Bureau Tadashi Allen, MD University of Minnesota Assistant Professor Diagnostic Radiology 10/29/2016 Outline Definition of
More informationAnnual Rheumatology & Therapeutics Review for Organizations & Societies
Annual Rheumatology & Therapeutics Review for Organizations & Societies A Rheumatologist s Approach to Interstitial Lung Disease Outline ILD classification and patterns in CTD The clinical landscape and
More informationPatient with IPF and no honeycombing on HRCT. Case 1 Demosthenes Bouros, Vasilios Tzilas University of Athens
Patient with IPF and no honeycombing on HRCT Case 1 Demosthenes Bouros, Vasilios Tzilas University of Athens CASE OVERVIEW A 76-year-old male patient presented with progressive exertional dyspnoea refractory
More informationDIFFERENCES IN FIBROPROLIFERATIVE HEALING IN EXOGENEOUS AND IDIOPATHIC ILDs. ARE THERE ANY?
NIHR Southampton Respiratory Biomedical Research Unit DIFFERENCES IN FIBROPROLIFERATIVE HEALING IN EXOGENEOUS AND IDIOPATHIC ILDs. ARE THERE ANY? Fibrosing Interstitial Lung Diseases CPFS/WASOG/AIPO/ERS
More informationControversies in Clinical Trials. Pirfenidone for Idiopathic Pulmonary Fibrosis (IPF)
Controversies in Clinical Trials Pirfenidone for Idiopathic Pulmonary Fibrosis (IPF) Controversies to be highlighted by IPF Post-hoc analyses Story Primary end point selection Changing prespecified endpoints
More informationTimely Topics in Pulmonary Medicine
Disclosures Timely Topics in Pulmonary Medicine I have nothing to disclose! Lorriana Leard, MD Associate Professor of Clinical Medicine Chief of Clinical Operations UCSF Pulmonary, Critical Care, Allergy
More informationManagement of Idiopathic Pulmonary Fibrosis
Management of Idiopathic Pulmonary Fibrosis Robert Hallowell, M.D. December 22, 2015 Disclosures No financial disclosures What causes IPF? +? VEGF-R Airspace lining TNFa Fibrocytes PDGF Fibroblasts IL-1
More informationIdiopathic pulmonary fibrosis
Pharmacologic Treatments for Idiopathic Pulmonary Fibrosis This chronic disease has historically lacked an effective treatment option, but the FDA recently approved two: pirfenidone and nintedanib. This
More informationLiebow and Carrington's original classification of IIP
Liebow and Carrington's original classification of IIP-- 1969 Eric J. Stern MD University of Washington UIP Usual interstitial pneumonia DIP Desquamative interstitial pneumonia BIP Bronchiolitis obliterans
More informationEpidemiology and classification of smoking related interstitial lung diseases
Epidemiology and classification of smoking related interstitial lung diseases Šterclová M. Department of Respiratory Diseases, Thomayer Hospital, Prague, Czech Republic Supported by an IGA Grant No G 1207
More informationDisclosures. Clinical Approach: Evaluating CTD-ILD for the pulmonologist. ILD in CTD. connective tissue disease or collagen vascular disease
Disclosures Clinical Approach: Evaluating CTD-ILD for the pulmonologist Industry relationships: Actelion, atyr Pharma, Boehringer-Ingelheim, Genentech- Roche, Gilead Aryeh Fischer, MD Associate Professor
More informationInterstitial Lung Disease ILD: Definition
Interstitial Lung Disease 2007 Paul F. Simonelli,, MD, PhD, FCCP Clinical Director Center for Interstitial Lung Disease Columbia University Medical Center 1. ILD is not one disorder ILD: Definition 2.
More informationPathologic Assessment of Interstitial Lung Disease
Pathologic Assessment of Interstitial Lung Disease Dry and itchy? It could be eczema or fungal infection. We don t need to worry, the drugs aren t that dangerous. Kirk D. Jones, MD UCSF Dept. of Pathology
More informationInternational consensus statement on idiopathic pulmonary fibrosis
Eur Respir J 2001; 17: 163 167 Printed in UK all rights reserved Copyright #ERS Journals Ltd 2001 European Respiratory Journal ISSN 0903-1936 PERSPECTIVE International consensus statement on idiopathic
More informationChallenges in the classification of fibrotic ILD
Review SARCOIDOSIS VASCULITIS AND DIFFUSE LUNG DISEASES 2015; 32; Suppl. 1: 4-9 Mattioli 1885 Challenges in the classification of fibrotic ILD Elisabeth Bendstrup 1, Toby M. Maher 2, Effrosyni D. Manali
More informationDisclosures. IPF Medications: Practical Experience. Prednisone, Azathioprine, N acyetylcysteine. Case 1. Brett Ley, MD, MAS Assistant Professor, UCSF
IPF Medications: Practical Experience Disclosures Received speakers bureau honorarium from Roche/Genentech (makers of pirfenidone). Brett Ley, MD, MAS Assistant Professor, UCSF 67 y/o man 1 year cough
More informationDo randomized clinical trials always provide certain results? The case of tralokinumab in idiopathic pulmonary fibrosis
Page 1 of 6 AJRCCM Articles in Press. Published on 25-August-2017 as 10.1164/rccm.201708-1666ED Do randomized clinical trials always provide certain results? The case of tralokinumab in idiopathic pulmonary
More informationUnpaid scientific collaborator & advisor with Veracyte, Inc.
Diagnosis and Classification of Idiopathic Interstitial Pneumonias: Role of Histopathology in the Golden Age of Consensus Jeffrey L. Myers, M.D. A. James French Professor of Diagnostic Pathology Vice Chair
More informationManish Powari Regional Training Day 10/12/2014
Manish Powari Regional Training Day 10/12/2014 Large number of different types of Interstitial Lung Disease (ILD). Most are very rare Most patients present with one of a smaller number of commoner diseases
More informationPFF HEALTH CARE PROFESSIONAL WEBINAR SERIES. Welcome!
PFF HEALTH CARE PROFESSIONAL WEBINAR SERIES Welcome! AGENDA TOPICS Welcome & Introduction Dr. Gregory Cosgrove, MD Chief Medical Officer Pulmonary Fibrosis Foundation PFF Resources Dolly Kervitsky, RCP,
More informationINTERSTITIAL LUNG DISEASE Dr. Zulqarnain Ashraf
Indep Rev Jul-Dec 2018;20(7-12) Dr. Zulqarnain Ashraf IR-653 Abstract: ILD is a group of diseases affect interstitium of the lung. Repeated insult to the lung cause the interstitium to be damaged. Similarly
More informationTBLB is not recommended as the initial biopsy option in cases of suspected IPF and is unreliable in the diagnosis of rare lung disease (other than
TBLB is not recommended as the initial biopsy option in cases of suspected IPF and is unreliable in the diagnosis of rare lung disease (other than PAP) BAL is not required as a diagnostic tool in patients
More informationGuide to Clinical Management of Idiopathic Pulmonary Fibrosis
Guide to Clinical Management of Idiopathic Pulmonary Fibrosis Steven D Nathan A Whitney Brown Christopher S King Guide to Clinical Management of Idiopathic Pulmonary Fibrosis Steven D Nathan Inova Fairfax
More informationRole of Pirfenidone in Idiopathic Pulmonary Fibrosis - A Longitudinal Cohort Study
36 Journal of The Association of Physicians of India Vol. 64 May 2016 Original Article Role of Pirfenidone in Idiopathic Pulmonary Fibrosis - A Longitudinal Cohort Study KP Suraj 1, Neethu K Kumar 2, E
More informationIdiopathic Pulmonary Fibrosis: State-of-the-Art Evaluation and Management: Comorbidities in IPF
Idiopathic Pulmonary Fibrosis: State-of-the-Art Evaluation and Management: Comorbidities in IPF Steven D. Nathan, MBBCh, FCCP Advanced Lung Disease &Transplant Program Inova Fairfax Hospital Professor
More informationIPF: Epidemiologia e stato dell arte
IPF: Epidemiologia e stato dell arte Clinical Classification Diffuse parenchimal lung diseases Exposure-related: - occupational - environmental - medication Desquamative interstitial pneumonia Idiopathic
More informationCome gestire le comorbidità e il follow-up
Come gestire le comorbidità e il follow-up Antonella Caminati U.O. di Pneumologia e Terapia Semi Intensiva Servizio di Fisiopatologia Respiratoria ed Emodinamica Polmonare Osp. San Giuseppe - MultiMedica,
More informationGuidelines for Diagnosis and Treatment of IPF
Guidelines for Diagnosis and Treatment of IPF Katerina Antoniou, MD, PhD Lecturer in Thoracic Medicine ERS ILD Group Secretary Medical School, University of Crete Classification of Interstitial Lung Disease
More informationChallenges in the Diagnosis of Interstitial Lung Disease
Challenges in the Diagnosis of Interstitial Lung Disease Kirk D. Jones, MD UCSF Dept. of Pathology kirk.jones@ucsf.edu Overview New Classification of IIP Prior classification Modifications for new classification
More informationTriple kinase inhibitor with phosphodiesterase-5 inhibitor for idiopathic pulmonary fibrosis
Editorial Triple kinase inhibitor with phosphodiesterase-5 inhibitor for idiopathic pulmonary fibrosis Tomoo Kishaba Department of Respiratory Medicine, Okinawa Chubu Hospital, Uruma City, Okinawa, Japan
More informationCurrent Management of IPF and. Dr R Lakshmi Narasimhan Dept of Pulmonary Medicine
Current Management of IPF and fibrosing ILDs Dr R Lakshmi Narasimhan Dept of Pulmonary Medicine Introduction Idiopathic pulmonary fibrosis clinical course is variable and long term survival is poor Therapy
More informationIPF - Inquadramento clinico
IPF - Inquadramento clinico Sergio Harari Unità Operativa di Pneumologia UTIR Servizio di Fisiopat. Resp. e Emodinamica Polmonare Ospedale S. Giuseppe, Milano Clinical Classification Diffuse parenchimal
More informationIDIOPATHIC PULMONARY FIBROSIS Guidelines for Diagnosis and Management
IDIOPATHIC PULMONARY FIBROSIS Guidelines for Diagnosis and Management An ATS Pocket Publication This publication was produced in collaboration with Boehringer Ingelheim Pharmaceuticals, Inc. GUIDELINES
More informationOctober 30, The Westin Princeton at Forrestal Village 201 Village Boulevard Princeton, NJ Marilyn Glassberg Csete, MD FACP, FCCP
October 3, 215 The Westin Princeton at Forrestal Village 21 Village Boulevard Princeton, NJ 854 Marilyn Glassberg Csete, MD FACP, FCCP Professor of Medicine, Surgery, and Pediatrics at the University of
More informationDisclosures. Transplanting Interstitial Lung Disease. Lung Transplantation. Indications. I have nothing to disclose. Adult Lung Transplants
Transplanting Interstitial Lung Disease Steven Hays, MD Associate Professor Medical Director, Lung Transplantation UCSF Medical Center Disclosures I have nothing to disclose Adult Lung Transplants Number
More informationDiagnosing ILD. What is important in 2016? Chris Grainge
Diagnosing ILD What is important in 2016? Chris Grainge Senior Staff Specialist Respiratory Medicine John Hunter Hospital Conjoint A/Prof University of Newcastle Conflict of interest I have acted as a
More informationExperience with the Compassionate Use Program of nintedanib for the treatment of Idiopathic Pulmonary Fibrosis in Argentina
ORIGINAL 131 RAMR 2017;2:131-135 ISSN 1852-236X Correspondence Gabriela Tabaj gabrielatabaj@gmail.com Received: 11.15.2016 Accepted: 02.03.2017 Experience with the Compassionate Use Program of nintedanib
More informationCOI: no conflicts of interest to declare
Idiopathic versus secondary Usual Interstitial Pneumonia (UIP) pattern in a series of 96 consecutive surgical lung biopsies: The value of histologic ancillary findings in a multidisciplinary discussion
More informationNONE OVERVIEW FINANCIAL DISCLOSURES UPDATE ON IDIOPATHIC PULMONARY FIBROSIS/IPF (UIP) FOR PATHOLOGISTS. IPF = Idiopathic UIP Radiologic UIP Path UIP
UPDATE ON IDIOPATHIC PULMONARY FIBROSIS/IPF () FOR PATHOLOGISTS Thomas V. Colby, M.D. Professor of Pathology (Emeritus) Mayo Clinic Arizona FINANCIAL DISCLOSURES NONE OVERVIEW IPF Radiologic Dx Pathologic
More informationIDIOPATHIC PULMONARY FIBROSIS UPDATE
IDIOPATHIC PULMONARY FIBROSIS UPDATE The Importance of Early Recognition and Referral 1 Learning objectives Recognize the importance of early diagnosis and treatment of idiopathic pulmonary fibrosis (IPF)
More informationCurrent diagnostic recommendations for ILD: The multidisciplinary meeting TSANZSRS ASM
Medicine, Nursing and Health Sciences Current diagnostic recommendations for ILD: The multidisciplinary meeting Dr Ian Glaspole Central and Eastern Clinical School, Alfred Hospital and Monash University
More informationCase 4 History. 58 yo man presented with prox IP joint swelling 2 months later pain and swelling in multiple joints Chest radiograph: bi-basilar
Case 4 History 58 yo man presented with prox IP joint swelling 2 months later pain and swelling in multiple joints Chest radiograph: bi-basilar basilar infiltrates suggestive of pulmonary fibrosis Open
More informationOn behalf of Lung Foundation Australia and the Thoracic Society of Australia and New Zealand. August 2017
On behalf of Lung Foundation Australia and the Thoracic Society of Australia and New Zealand Treatment of Idiopathic Pulmonary Fibrosis in Australia and New Zealand from the Thoracic Society of Australia
More informationUIP OR NOT UIP PATTERN: THAT IS NOT THE ONLY QUESTION!
UIP OR NOT UIP PATTERN: THAT IS NOT THE ONLY QUESTION! STÉPHANE JOUNEAU 11 JULY 2014 Respiratory Medicine Department, Pontchaillou Hospital, Rennes, France CASE OVERVIEW This case highlights how a usual
More informationERS 2016 Congress Highlights Interstitial Lung Disease (ILD)
ERS 216 Congress Highlights Interstitial Lung Disease (ILD) London, UK September 3 rd 7 th 216 The 26 th European Respiratory Society International Congress, (ERS) the largest respiratory meeting in the
More informationPNEUMOLOGIA 2018 Milano, giugno 2018 INTERSTIZIOPATIE E MALATTIE RARE. Il futuro dell IPF: dove stiamo andando. Carlo Albera
PNEUMOLOGIA 2018 Milano, 14 16 giugno 2018 INTERSTIZIOPATIE E MALATTIE RARE Il futuro dell : dove stiamo andando Carlo Albera Università di Torino, Scuola di Medicina Dipartimento di Scienze Cliniche e
More informationSummary: Key Learning Points, Clinical Strategies, and Future Directions
Summary: Key Learning Points, Clinical Strategies, and Future Directions Introduction Idiopathic pulmonary fibrosis (IPF), a peripheral lobular fibrosis of unknown cause, is a chronic, progressive lung
More information9/15/11. Dr. Vivien Hsu Director, UMDNJ Scleroderma Program New Brunswick, NJ September Scleroderma. Hard skin
Dr. Vivien Hsu Director, UMDNJ Scleroderma Program New Brunswick, NJ September 2011 Scleroderma Hard skin 1 No diagnostic test for scleroderma Pathogenesis is unknown prominent features of disease reflect
More informationIdiopathic pulmonary fibrosis: recent advances on pharmacological therapy
Accepted Manuscript Idiopathic pulmonary fibrosis: recent advances on pharmacological therapy P. Spagnolo, T.M. Maher, L. Richeldi PII: S0163-7258(15)00091-1 DOI: doi: 10.1016/j.pharmthera.2015.04.005
More informationNon-neoplastic Lung Disease II
Pathobasic Non-neoplastic Lung Disease II Spasenija Savic Prince Pathology Program Systematic approach to surgical lung biopsies with ILD Examples (chronic ILD): Idiopathic interstitial pneumonias: UIP,
More informationIdiopathic Pulmonary Fibrosis: A Study of 46 Patients from Western India: Clinical Presentations and Survival
Turk Thorac J 205; 6:4-20 DOI: 0.552/ttd.205.4584 ORIGINAL INVESTIGATION Idiopathic Pulmonary Fibrosis: A Study of 46 Patients from Western India: Clinical Presentations and Survival Subramanian Natarajan,
More informationKD : A Phase 2 Trial of KD025 to Assess Safety, Efficacy and Tolerability in Patients with Idiopathic Pulmonary Fibrosis (IPF)
-207: A Phase 2 Trial of to Assess Safety, Efficacy and Tolerability in Patients with Idiopathic Pulmonary Fibrosis (IPF) K. F. Gibson 1, F. Averill 2, T.E. Albertson 3, D. M. Baratz 4, S. Chaudhary 5,
More informationDifficulties Diagnosing Idiopathic Pulmonary Fibrosis
1. er Encuentro Entre Neumólogos y Radiólogos, Madrid, Spain, 2016, October 14th Difficulties Diagnosing Idiopathic Pulmonary Fibrosis Simon Walsh King s College Hospital Foundation Trust London, United
More informationMultidisciplinary Diagnosis in Action: Challenging Case Presentations
Multidisciplinary Diagnosis in Action: Challenging Case Presentations Interstitial Lung Disease: Advances in Diagnosis and Management UCSF CME November 8, 2014 Case 1 69 yo M 3 year history of intermittent
More information